Validation Data Gallery

  • 1X10^6 HEK LAG3 transient transfected cells (red) and HEK parental cells were surface stained with 0.25 µg FITC Plus conjugated-LAG3 VHH (FITC-lt). Cells were not fixed.

    1X10^6 HEK LAG3 transient transfected cells (red) and HEK parental cells were surface stained with 0.25 µg FITC Plus conjugated-LAG3 VHH (FITC-lt). Cells were not fixed.

  • Live HeLa cells transfected with human LAG3 were immunostained FITC Plus conjugated-LAG3 VHH (FITC-lt, 1:500, green). Cells were fixed and nuclei were stained with DAPI (cyan). Epifluorescence images were acquired with a 20x objective and post-processed. 
Note: Immunostaining with FITC-lt can also be performed after formaldehyde fixation of the cells.

    Live HeLa cells transfected with human LAG3 were immunostained FITC Plus conjugated-LAG3 VHH (FITC-lt, 1:500, green). Cells were fixed and nuclei were stained with DAPI (cyan). Epifluorescence images were acquired with a 20x objective and post-processed.  Note: Immunostaining with FITC-lt can also be performed after formaldehyde fixation of the cells.

  • Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) and CL405 CD3 (CL405-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.

    Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) and CL405 CD3 (CL405-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.5ug FITC Plus conjugated LAG-3 VHH (FITC-lt) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.

ChromoTek FITC Plus-conjugated LAG3 VHH

FITC-lt targets LAG3 in FC and IF applications and shows reactivity with Human samples.
Cat No. FITC-lt

Host/Type

Alpaca VHH

Reactivity

Human

Applications

FC, IF

Conjugate

FITC Plus

LAG3-Nanobody, LAG3-single domain antibody (sdAb), CD223, FDC, LAG 3, LAG3, LAG-3, lymphocyte activation gene 3, Protein FDC

Size/Concentration: 

-/ -


ご購入について

国内販売は「コスモ・バイオ株式会社」を通じて行っております。お見積り・ご注文はお近くの販売代理店へご連絡ください。


国内在庫・納期について

約2万点のプロテインテック製品をコスモバイオ社物流センター(国内)に在庫しています。国内在庫の有無はコスモバイオ社ホームページの「品番検索」でカタログ番号を検索して確認できます。


保証・サポートについて

テクニカルサポートまたはご購入後1年間の交換/補填対応を承ります。詳細はこちらをご覧ください。


Product Information

FITC-lt targets LAG3 in FC and IF applications and shows reactivity with Human samples.

ApplicationsFC, IF
ReactivityHuman
ConjugateFITC Plus
Type Nanobody
ClassRecombinant
HostAlpaca
AffinityPicomolar range, below the assay limit (biolayer interferometry)
Molecular Weight15.141 kDa
FormLiquid
Excitation/Emission Maxima Wavelengths495 nm / 524 nm
RRIDAB_3101919
Storage Buffer500 mM NaCl, 10 mM HEPES pH 7.0, 5 mM EDTA, 0.09% sodium azide
Storage ConditionStore at -20°C; Shipped at ambient temperature.
BackgroundLAG-3, also known as CD223, is an immune checkpoint molecule that regulates both T-cell activation and homeostasis. LAG-3 is expressed on activated T cells, NK cells, regulatory T cells, and plasmacytoid dendritic cells. It is a CD4-related molecule that binds MHC class II. LAG-3 plays an important role in modulating T cell expansion and function, and blockade of LAG-3 with monoclonal antibodies can augment T cell function. (PMID: 15634887; 21086108; 28783703)